Samsung C&T (028260) investor relations material

Executive summary

• Q2 2026 sales reached KRW 11.995 trillion and operating profit was KRW 1.032 trillion, with operating margin at 8.6%.

• Sales and operating profit increased both sequentially and year-over-year, driven by E&C Hi-Tech projects, robust T&I trading, and Bio segment growth.

• Net profit for Q2 was KRW 916 billion, with pre-tax profit at KRW 1.077 trillion.

• Strategic investments and acquisitions in energy, data centers, and life sciences to capture emerging market opportunities.

Financial highlights

• Q2 sales rose KRW 1.529 trillion and operating profit by KRW 312 billion sequentially; YoY, sales up KRW 1.973 trillion and OP up KRW 279 billion.

• Non-operating loss was KRW 11 billion; financial profit and equity method gain totaled KRW 56 billion.

• Total assets at end-Q2: KRW 163.769 trillion; total equity: KRW 113.709 trillion; debt decreased to KRW 3.087 trillion.

• Debt to equity ratio improved to 44% from 50% in Q1; current ratio at 150%, borrowing dependency at 1.9%.

• Net cash position increased to KRW 4.683 trillion; operating cash flow for 1H26 at KRW 3.653 trillion.

Outlook and guidance

• Q3 sales and operating profit growth expected to continue, with further acceleration in H2 2026.

• E&C Hi-Tech investment cycle anticipated to last several years, with full-year revenue and OP to exceed original guidance.

• T&I expects Q3 moderation due to commodity downturn and EU steel quotas, but aims for full-year diversification and margin improvement.

• Fashion and F&B to pursue earnings improvement for full year despite potential Q3 moderation.

• Biologics expects annual sales growth of 15–20% YoY and Epis Holdings sales to grow over 10% YoY.